The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery
Open accessAbstract
Purpose: Approximately 12,000 glioblastomas are diagnosed annually in the United States. The median survival rate for this disease is 12 months, but individual survival rates can vary with patient-specific factors, including extent of surgical resection (EOR). The goal of our investigation is to develop a reliable strategy for personalized survival prediction and for quantifying the relationship between survival, EOR, and adjuvant chemoradiotherapy. Patients and Methods: We used accelerated failure time (AFT) modeling using data from 721 newly diagnosed patients with glioblastoma (from 1993 to 2010) to model the factors affecting individualized survival after surgical resection, and we used the model to construct probabilistic, patient-specific tools for survival prediction. We validated this model with independent data from 109 patients from a second institution. Results: AFT modeling using age, Karnofsky performance score, EOR, and adjuvant chemoradiotherapy produced a continuous, nonlinear, multivariable survival model for glioblastoma. The median personalized predictive error was 4.37 months, representing a more than 20% improvement over current methods. Subsequent model-based calculations yield patient-specific predictions of the incremental effects of EOR and adjuvant therapy on survival. Conclusion: Nonlinear, multivariable AFT modeling outperforms current methods for estimating individual survival after glioblastoma resection. The model produces personalized survival curves and quantifies the relationship between variables modulating patient-specific survival. This approach provides comprehensive, personalized, probabilistic, and clinically relevant information regarding the anticipated course of disease, the overall prognosis, and the patient-specific influence of EOR and adjuvant chemoradiotherapy. The continuous, nonlinear relationship identified between expected median survival and EOR argues against a surgical management strategy based on rigid EOR thresholds and instead provides the first explicit evidence supporting a maximum safe resection approach to glioblastoma surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
An extent of resection threshold for newly diagnosed glioblastomas: Clinical article
Sanai, N., Polley, M.-Y., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,646
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
MR imaging correlates of survival in patients with high-grade gliomas.
Pope, W. B., Sayre, J. W., Perlina, A., Villablanca, J. P., Mischel, P. S., & Cloughesy, T. F. (2005) · PubMed Central · Cited by 418
Keles, G. E., Anderson, B., & Berger, M. S. (1999) · Surgical Neurology · doi:10.1016/s0090-3019(99)00103-2 · Cited by 366
Survival Analysis: Techniques for Censored and Truncated Data
Langner, I. (2006) · Biometrics · doi:10.1111/j.1541-0420.2006.00589_9.x · Cited by 346
Keles, G. E., Chang, E. F., Lamborn, K. R., Tihan, T., Chang, C.-J., Chang, S. M., & Berger, M. S. (2006) · Journal of Neurosurgery · doi:10.3171/jns.2006.105.1.34 · Cited by 229
Extent of resection influences outcomes for patients with gliomas
Sanai, N., & Berger, M. S. (2011) · Revue Neurologique · doi:10.1016/j.neurol.2011.07.004 · Cited by 156
The Value of Glioma Extent of Resection in the Modern Neurosurgical Era
Hardesty, D. A., & Sanai, N. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00140 · Cited by 132
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Li, Y. M., Suki, D., Hess, K., & Sawaya, R. (2016) · Journal of Neurosurgery · doi:10.3171/2015.5.jns142087 · Cited by 646
Self-citationMolinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Overcoming therapeutic resistance in glioblastoma: the way forward
Osuka, S., & Van Meir, E. G. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 511
Metadata
- Authors
- Marko, N. F., Weil, R. J., Schroeder, J. L., Lang, F. F., Suki, D., & Sawaya, R. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-03-10
- Volume
- 32
- Issue
- 8
- Pages
- 774-782
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162496354
- Cited by
- 315
- References
- 18
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.